Long-term Outcomes of Clinical Node-Positive Prostate Cancer Patients Treated with Radical Prostatectomy as Part of a Multimodal Treatment: Patterns of Recurrence and Competing-Risk Mortality

Gandaglia G.1, Karnes JR.2, Devos G.3, Berghen C.4, Everaerts W.3, Motterle G.2, Joniau S.3, Cincikaaer A.3, Scuderi S.1, Robest D.1, Canoletta D.1, Scalvi F.1, Fossatin N.1 Van Poppel, H.2, Cucchiara V.1, Rizzo A.1, Zito E.1, Dehò F.1, Droghetti M.1, Pellegrino A.1, Stabile A.1, Martini A.1, Montorsi F.1, Briganti A.1

1Unit of Urology/Division of Oncology, URI, IRCCS Centocelle, Rome, Italy; 2Department of Urology, Mayo Clinic, Rochester, MN, USA; 3Department of Urology, University Hospitals Leuven, Belgium; 4University Hospitals Leuven, Department of Radiotherapy, Leuven, Belgium.

INTRODUCTION

Although curative-intent therapies such as radical prostatectomy (RP) have been proposed as therapeutic options in prostate cancer (PCa) patients with enlarged lymph nodes at imaging (cN1), no data is available on the long-term outcomes and patterns of recurrence of surgically managed cN1 patients.

MATERIALS AND METHODS

A total of 350 patients with cN1 PCa in the pelvis and/or retroperitoneum detected by conventional (namely, abdominal CT or MRI, 85%) or molecular imaging (namely Choline or PSMA PET scan, 15%) who received RP and pelvic ± retroperitoneal lymph node dissection (LND) between 2005 and 2019 at three centers were identified. Clinical recurrence (CR) was defined as the onset of metastases detected by conventional imaging. The site of the first CR was stratified as follows: (i) local (prostatic fossa and regional nodes), (ii) retroperitoneal, and (iii) distant (skeletal and visceral metastases). Kaplan-Meier analyses assessed time to CR and cancer-specific mortality (CSM) after stratifying patients according to the first site of CR. Cox regression analyses assessed predictors of CR after adjusting for adjuvant treatments. Poisson smoothed cumulative incidence plots assessed 10-year CSM and other cause mortality (OCM) after stratifying patients according to a risk score based on pathologic features associated with CSM.

RESULTS

CONCLUSIONS

Up to one out of four patients with clinical lymphadenopathies treated with surgery in a multimodal setting experience CR in the prostatic fossa or pelvic nodes. These patients harbour more favourable outcomes as compared to those who experience retroperitoneal or distant metastases. Pathologic grade group and SVI are predictors of distant CR. When patients are stratified according to these parameters, men with a grade group 1-3 and no SVI are at substantially higher risk of dying from other causes than the disease itself. These data should be considered to counsel patients and avoid overtreatment.